Search

Ketorolac

Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. … disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis.

Isradipine

It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. … It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells

Butylene glycol

Risperidone

[L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways … Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder.

Lonoctocog alfa

Trimebutine

Trimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries. … It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form.

Propiverine

Overactive bladder syndrome affects millions of elderly individuals in the United States and shows equal prevalence in men and women. … Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the night to urinate)

Anethole trithione

inhibit carcinogenesis by increasing the activity of electrophile detoxification enzymes [A32619], and even being used as an adjunctive therapy for cholecystitis, gallstone, indigestion, and acute/chronic … hepatitis [L2388] and is marketed in certain countries like France, Germany, and China [A32614].

Panitumumab

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. … Panitumumab was granted FDA approval on 27 September 2006.[L17663]

Inclisiran

[A225953,A225958] Lowering circulating plasma LDL-C levels offers an additional benefit of reducing the risk of cardiovascular disease (CVD) and improving cardiovascular outcomes, as hypercholesterolemia … (heterozygous familial and non-familial) or mixed dyslipidemia, alone or in combination with other lipid-lowering therapies.